source
- Pfizer sells Seagen-derived ADC to Medicus Pharma for $12 million upfront, potential $1 billion milestonesPfizer has transferred rights to an antibody‑drug conjugate it acquired in its Seagen purchase to Medicus Pharma. Medicus will pay $12 million upfront and $15 million a year later, and Pfizer coul…
- GSK agrees $1.3 billion deal with Hutchmed for early-stage KRAS-EGFR cancer candidateGSK will pay $110 million upfront to Hutchmed as part of a deal that could reach $1.295 billion, giving GSK worldwide rights to develop and commercialize a preclinical oncology asset. The asset, i…